ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1734

Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study

Nadia Tchao1, Hamid Amouzadeh2, Nandita Sarkar1, Vincent Chow2, Xuguang Hu1, Mark Kroenke2, Hui Wang2, Rong Zhang2, Kevin Gorski1, Richard Furie3, Alan Kivitz4 and Stanley Cohen5, 1Amgen Inc., South San Francisco, CA, 2Amgen Inc., Thousand Oaks, CA, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Altoona Center for Clinical Research, Duncansville, PA, 5Metroplex Clinical Research Center, Dallas, TX

Meeting: ACR Convergence 2021

Keywords: Biologicals, clinical trial, Interleukins, Systemic lupus erythematosus (SLE), Treg cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: SLE – Treatment Poster (1732–1772)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE. Efavaleukin alfa is a novel IL-2 mutein Fc fusion protein designed to selectively expand Treg. In healthy subjects, a single dose of efavaleukin alfa was well tolerated and demonstrated Treg selectivity with minimal changes in CD4+ conventional T cells (Tcon), CD8+ T cells, or NK cells (Tchao N Blood 2017). This interim analysis of an ongoing phase 1b study (NCT03451422) reports the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic effects of multiple doses of efavaleukin alfa in patients with SLE.

Methods: Four of five ascending dosing cohorts are reported in this analysis. A total of 29 patients with SLE (age 18-70 years; 82.8% female; SLE diagnosed using SLICC or ACR criteria with ANA ≥1:80 and/or elevated anti-dsDNA antibodies) were randomized to receive efavaleukin alfa or placebo (5:2 ratio for cohorts 1–3; 3:1 ratio for cohort 4) subcutaneously every 2 weeks (Q2W; cohorts 1, 2, and 4) or every week (QW; cohort 3) in addition to standard of care therapy for a total of 12 weeks, with 6 weeks of follow-up. Endpoints assessed in this analysis included treatment-emergent adverse events (TEAEs), serum PK profiles of efavaleukin alfa, changes in numbers of Treg, CD4+ Tcon, CD8+ T cells, and NK cells, and levels of cytokines in peripheral blood.

Results: The most commonly reported TEAEs (≥25% of all subjects) included non-serious, mild or moderate (grade 1–2) injection site reactions. No dose-limiting toxicities, treatment-related serious AEs, or deaths were reported. Efavaleukin alfa PK was generally linear and dose-proportional, with a terminal half-life ranging from 18 to 30 hours. Peak Foxp3+ Treg expansion was observed at 8 days post-dose, and the magnitude of the peaks was generally sustained after multiple QW or Q2W doses. Treg numbers remained above baseline for an average of 42 days after the last dose (Figure 1). The mean peak increases in Foxp3+ Treg were 17.4-, 5.7-, 2.4-, and 1.1-fold above baseline for the high, middle, and low Q2W efavaleukin alfa and placebo cohorts, respectively. At the highest dose, the mean peak increase in CD25bright Treg was 53.8-fold above baseline (Figure 2). Treatment with efavaleukin alfa expanded CD31+ recent thymic emigrant and naïve Treg populations; increases in these Treg subsets persisted longer than increases in memory Treg subsets. The majority of expanded Treg expressed markers associated with suppressive activity, including Helios, PD-1, ICOS, CD39, and GITR. There were no meaningful changes in numbers of CD4+ Tcon, CD8+ T cells, or NK cells or serum levels of pro-inflammatory cytokines with treatment.

Conclusion: Multiple doses of efavaleukin alfa were well tolerated in SLE patients. Treatment with efavaleukin alfa resulted in robust and prolonged dose-dependent Treg expansion, with minimal changes in other IL-2-responsive cells highlighting pharmacodynamic selectivity. These findings confirm and extend previous results in healthy subjects and support the ongoing phase 2b adaptive randomized controlled trial in patients with SLE.


Disclosures: N. Tchao, Amgen Inc, 3, 11; H. Amouzadeh, Amgen Inc, 3, 11; N. Sarkar, Amgen Inc, 3, 11; V. Chow, Amgen Inc, 3, 11; X. Hu, Amgen Inc, 3, 11; M. Kroenke, Amgen Inc, 3, 11; H. Wang, Amgen Inc, 3, 11; R. Zhang, Amgen Inc, 3, 11; K. Gorski, Amgen Inc, 3, 11; R. Furie, GlaxoSmithKline, 2, 5; A. Kivitz, Pfizer, 2, 6, 11, 12, Sanofi, 2, 6, 11, 12, GlaxoSmithKline, 11, Gilead Sciences, Inc.,, 2, 11, Novartis, 2, 6, 12, AbbVie, 2, 6, 11, Boehringer Ingelheim, 2, Janssen, 2, Regeneron, 2, 6, 12, SUN Pharma Advanced Research, 2, Amgen, 11, Lilly, 6, Celgene, 6, 12, Flexion, 2, 6, Genzyme, 2, 6, 12, Merck, 6, 12, UCB, 6, Horizon, 6, 12; S. Cohen, Amgen Inc, 1, 2, 5, AbbVie, 1, 2, 5, Pfizer, 1, 2, 5, Genentech, 1, 2, 5, Eli Lilly, 1, 2, 5, Gilead, 1, 2, 5.

To cite this abstract in AMA style:

Tchao N, Amouzadeh H, Sarkar N, Chow V, Hu X, Kroenke M, Wang H, Zhang R, Gorski K, Furie R, Kivitz A, Cohen S. Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/efavaleukin-alfa-a-novel-il-2-mutein-selectively-expands-regulatory-t-cells-in-patients-with-sle-interim-results-of-a-phase-1b-multiple-ascending-dose-study/. Accessed January 31, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efavaleukin-alfa-a-novel-il-2-mutein-selectively-expands-regulatory-t-cells-in-patients-with-sle-interim-results-of-a-phase-1b-multiple-ascending-dose-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences